KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Research & Development (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Research & Development readings, the most recent being $40.9 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 17.34% to $40.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $166.1 million, a 4.87% decrease, with the full-year FY2025 number at $166.1 million, down 4.87% from a year prior.
  • Research & Development hit $40.9 million in Q4 2025 for Biocryst Pharmaceuticals, down from $44.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $73.2 million in Q4 2022 to a low of $37.3 million in Q1 2025.
  • Median Research & Development over the past 5 years was $48.9 million (2023), compared with a mean of $51.0 million.
  • Biggest five-year swings in Research & Development: soared 92.28% in 2021 and later fell 29.42% in 2024.
  • Biocryst Pharmaceuticals' Research & Development stood at $63.5 million in 2021, then increased by 15.23% to $73.2 million in 2022, then decreased by 4.31% to $70.1 million in 2023, then decreased by 29.42% to $49.4 million in 2024, then dropped by 17.34% to $40.9 million in 2025.
  • The last three reported values for Research & Development were $40.9 million (Q4 2025), $44.6 million (Q3 2025), and $43.4 million (Q2 2025) per Business Quant data.